HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Turner, M. D. Articles by Kleinman, M. S. Search for Related Content PubMed Articles by Turner, M. D. Articles by Kleinman, M. S.

Further Purification of Perchlorate-Soluble Antigens from Human Colonic Carcinomata¹

From the Isaac Gordon Laboratory for Gastrointestinal Research, University of Rochester School of Medicine and Dentistry, 260 Crittenden Boulevard, Rochester, New York 14642

Abstract

Carcinoembryonic antigen (CEA) from colonic carcinoma extracts was labeled with radioiodine. The ¹²⁵ICEA appeared homogenous in a number of systems but showed three components on density gradient ultracentrifugation in CsCl. The component of intermediate density appeared to represent purified CEA and reacted vigorously with absorbed rabbit and goat anti-CEA sera. The most dense component reacted with antiserum to blood group A substance as well as with the two anti-CEA sera. Its reactivity with all three antisera was abolished by the addition of blood group A substance. The purified CEA also reacted weakly with anti-blood group A serum. This reaction was abolished by the addition of blood group substance which, however, had no effect on the reaction of the purified CEA with the anti-CEA sera. It was concluded that some preparations of tumor antigen contain a mixture of blood group A substance and the tumor antigen. The rabbit and goat anti-CEA sera appeared to contain a mixture of anti-CEA and anti-A antibodies. CEA molecules may contain both "CEA-determinants" and A-determinants. A sensitive radioimmunoassay for CEA was developed by using ¹²⁵I-labeled purified CEA.

Footnotes

¹ Supported by Grant 5-TO-1-AM-05177 from the National Institute of Arthritis and Metabolic Diseases, Center Grant CA-11198 from National Cancer Institute, and by General Research Support Grant RR-05403 from the National Institutes of Health.

² Advanced Clinical Fellow of the American Cancer Society.